Sistemas Medicos Nacionales becomes first international payer to
cover GPS Cancer™ for patients, bringing a new standard of cancer care
to Mexico
CULVER CITY, Calif.--(BUSINESS WIRE)--
NantHealth,
Inc. (Nasdaq: NH), a leading next-generation, evidence-based,
personalized healthcare company, today announced that GPS
Cancer, a molecular test that helps guide cancer treatment
strategies including choice of standard chemotherapy for oncologists, is
now covered by Sistemas
Medicos Nacionales, S.A. de C.V. (SIMNSA), a comprehensive
healthcare service plan that provides quality care for patients in the
cities of Tijuana, Tecate and Mexicali. With the availability and
coverage of GPS Cancer, oncologists can now provide patients in northern
Mexico with a more precise, personalized approach to their cancer care.
The partnership marks the next step in the international expansion of
GPS Cancer, which was recently also made available in Italy, Israel and
the Middle East.
“In 2012, the cancer incidence rate in Mexico stood at 148,000i
and continue to rise,” said Patrick Soon-Shiong, MD, CEO of NantHealth.
“We’re excited about the availability and coverage of GPS Cancer in
Mexico and believe this news is supporting our ongoing commitment to the
fight against cancer. We will continue with our global efforts to strive
to usher in the era of quantitative proteomics and personalized
treatment plans.”
The most common cancer types in Mexico are breast, colon, prostate and
cervix. Under the terms of the agreement, SIMNSA will cover GPS Cancer
for approximately 47,000 members in its healthcare plan. As one of the
most prominent Health Maintenance Organization (HMO) programs in
northern Mexico, SIMNSA was the first Mexican HMO to be licensed as a
healthcare service plan by the state of California. It is also one of
the largest private healthcare delivery systems in Baja, California,
with more than 200 participating physicians covering all specialties of
medicine.
“Our partnership with NantHealth is an important step in advancing
SIMNSA’s progress in establishing more advanced cancer care for patients
in Mexico,” said Christina Suggett, Chief Operating Officer, SIMNSA
Health Plan. “SIMNSA is in the ideal position to bring the GPS Cancer
test to Mexico and we’re proud to offer a tailored approach to their
cancer treatment plans.”
GPS Cancer, a unique molecular profile performed in the CLIA-certified,
CAP-accredited laboratories of NantOmics, integrates whole genome (DNA)
sequencing, whole transcriptome (RNA) sequencing, and quantitative
proteomics to provide oncologists with a comprehensive molecular profile
of a patient’s cancer to inform personalized treatment strategies. GPS
Cancer provides critical insights based on the unique biology of a
patient’s tumor—from the DNA to the RNA to the protein. The richness of
this information helps doctors to build potentially more effective
treatment plans based on current drugs and active clinical trials, while
enabling cancer researchers to design new clinical trials that harness
the potential of the immune system.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding the capabilities and
anticipated utility of our GPS Cancer, including predicting patient
response and resistance to therapeutics, enabling diagnoses by
physicians and accelerating efforts to bring novel combinations of
therapeutic agents to cancer patients. Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results. Factors
that may cause future results to differ materially from management’s
current expectations include, among other things, that GPS Cancer may
not perform as anticipated, that sufficient physicians may not adopt GPS
Cancer to assist their diagnoses or that healthcare payers may not
provide reimbursement for GPS Cancer as expected. Our business is
subject to numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of our products; our ability
to successfully launch new products and applications; competition; our
sales, marketing and distribution capabilities; our planned sales,
marketing, and research and development activities; unanticipated
increases in costs or expenses; and risks associated with international
operations. Information on these and additional risks, uncertainties,
and other information affecting our business and operating results can
be found in our existing and future filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of
the date hereof. We disclaim any obligation to update these
forward-looking statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth's unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissues and integrates
this molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system, which includes its unique
software, middleware and hardware systems infrastructure that collects,
indexes, analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and traditional
sources, continuously improves decision-making and further optimizes our
clinical pathways and decision algorithms over time. For more
information please visit www.nanthealth.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular scan available through NantHealth.
GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome
(RNA) sequencing, and quantitative proteomics through mass spectrometry,
providing oncologists with a comprehensive molecular profile of a
patient's cancer and an assessment of protein pathway function to inform
personalized treatment strategies. GPS Cancer scanning is conducted in
CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer
Breakthroughs 2020, the world's most comprehensive cancer
collaborative initiative seeking to accelerate the potential of
combination immunotherapy as the next generation standard of care in
cancer patients. For more information, visit www.gpscancer.com.
i See http://www.cancerindex.org/Mexico.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170807005591/en/
NantWorks
Jen Hodson
johodson@nantworks.com
Source: NantHealth, Inc.